QualityStocks'  Instablog

Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Oculus Innovative Sciences (OCLS) to Collaborate with Amneal Pharmaceutical Alliance 0 comments
    Feb 15, 2011 2:05 PM | about stocks: OCLS

    Amneal Enterprises, an affiliation of independent pharmaceutical businesses, has announced the formation of a multi-year and multi-product collaboration with Oculus Innovative Sciences, Inc., an innovator and developer of tissue care products based upon the Microcyn® Technology platform.

    The agreement calls for AmDerma, an Amneal alliance member, to pay Oculus $500,000 as a non-refundable initial payment for an option to license Microcyn technology for the treatment of acne. It also calls for Quinnova Pharmaceuticals, another Amneal member, to pay $500,000 to Oculus, along with double-digit royalties, for the U.S. and Canadian rights to Microcyn-based dermatology atopic dermatitis hydrogel. In addition, under the agreement, Amneal will co-promote the current Rx Microcyn-based wound care products to podiatry professionals in the U.S. and Canada.

    Oculus CEO, Hoji Alimi, spoke of the importance of the agreement to Oculus. “This next-generation collaboration is an important milestone for Oculus. The breadth of the resources of the Amneal Enterprises alliance members — encompassing multiple sites, nearly a thousand employees and hundreds of scientists — are complemented by their demonstrated ability to perform. In just a few short years, Amneal Pharmaceuticals, a member of the Amneal Enterprises alliance, has become the ninth largest provider of generic prescriptions in the United States as well as the fastest growing company in the highly competitive U.S. generics industry — and also looking towards the development of new drugs. Together, we can advance towards realizing what we have always believed to be the extraordinary promise of Microcyn.”

    The Oculus tissue care products based upon Microcyn Technology significantly reduce the need for antibiotics while reducing infections and accelerating healing. They successfully address the need for improved solutions in multiple markets, including dermatology, oral care, cosmeceutical, wound care and others. Several have demonstrated an ability to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria (including MRSA and VRE), viruses, fungi and spores, increasing blood flow to the wound site, and reducing both inflammation and pain while assisting in faster wound closure.

    For additional information, see the company’s website at Oculusis.com

    Please see disclaimer on QualityStocks website: disclaimer.qualitystocks.net

    Stocks: OCLS
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.